Investigations

Every investigation we've published, newest first — each one built on primary documents and classified under our evidence standard.

Topics Corporations·Government·Institutions·Public Figures·Fraud & Deception·Media
Institutions — 29 October 2024 — 7 min read

Amedisys: The $106 Million DOJ Settlement Over Therapy Minute Inflation at the Home Health Giant

Amedisys agreed to pay $106 million to the DOJ to resolve allegations that the home health company had instructed its therapists to inflate therapy minutes documented in patient records to push patients above the thresholds that triggered higher Medicare reimbursement tiers — a systematic upcoding scheme affecting thousands of patients across the company's national home health operations.

Read the full report
Corporations — 28 October 2024 — 7 min read

Medline: $85M GPO administrative resolution

Medline Industries paid $85 million to resolve allegations that administrative fees and rebates paid to a major hospital purchasing cooperative exceeded what the anti-kickback statute's GPO safe harbor permits, steering member hospital purchasing toward Medline products purchased with Medicare and Medicaid funds.

Read the full report
Fraud & Deception — 22 October 2024 — 7 min read

Monat Global: The Hair Care MLM the FTC Found Making Misleading Income Claims to Recruit Market Partners

The FTC investigated Monat Global over income representations made to prospective recruits for the company's hair care multi-level marketing program, finding that the earnings claims prominently featured in recruiting materials were not representative of the typical participant experience and constituted deceptive advertising under federal consumer protection law.

Read the full report
Corporations — 17 October 2024 — 7 min read

Lucira Health: The SEC Charged the At-Home COVID Test Maker With Failing to Disclose Obsoleting Inventory Before Its IPO

The SEC charged Lucira Health with omitting from its IPO registration statement material information about inventory obsolescence risk for its COVID-19 test kits — information that, had it been disclosed, would have materially altered investors' assessment of the company's near-term revenue prospects at the time of the offering.

Read the full report